MedTech I.Q.

The Cutting Edge of Medical Technology Content, Community & Collaboration

Colleagues,

I know that a number of MedTech-IQ members are committed to developing next generation biodefense early warning and diagnostic systems.  This new funding opportunity should be of interest to you ...

ENJOY!

CC
-------------------------------------------------------

Anthrax

This Funding Opportunity Announcement (FOA), is issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and invites applications for early stage product development projects to establish proof-of-concept for potential next generation diagnostics products that do not involve nucleic acid amplification ...


... The NIAID intends to commit $9 million in total costs in FY2011 to fund 7 to 10 awards ...

...
Budgets for direct costs of up to $750,000 per year and a project duration of 5 years may be requested, or $3,750,000 ... 

... In response to threats presented by bioterrorism and emerging infectious diseases, the NIAID Division of Microbiology and Infectious Diseases (DMID) has established research programs to facilitate development of countermeasures for certain pathogens and toxins ...

...
Through this funding opportunity, the NIAID invites applications to establish proof-of-concept for novel or emerging, rapid and innovative clinical diagnostic technologies, that do not involve nucleic acid amplification methods to detect NIAID Category A, B, or C Priority Pathogens and toxins (agents) (http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/resear...)...


...
Applications that include collaborations between researchers from different disciplines and/or with industry are strongly encouraged but not required...

Release/Posted Date:  July 8, 2010
Letters of Intent Receipt Date: October 4, 2010
Application Due Date: November 4, 2010 
 

...
At the end of the project period, a successful project will demonstrate the capability of the developed technology to detect targeted agents in live infectious disease animal models (for in vivo detection technologies) or human clinical samples (for other technologies).   Projects must assess the potential of the early stage diagnostic technology for large-scale production and utilization for diagnosis of infectious diseases in clinical settings, including public health laboratories, hospital-based clinical microbiology laboratories, and/or point-of-care use...

Read on at: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-10-017.html

Views: 11

© 2017   Created by CC-Conrad Clyburn-MedForeSight.   Powered by

Badges  |  Report an Issue  |  Terms of Service